Synteract Acquires Dermatology Specialist CRO Cu-Tech, Adding Center of Development in Dermatology

Synteract,
an innovative contract research organization (CRO) providing
full-service Phase I-IV clinical trials, has acquired Cu-Tech,
LLC, the leading dermatology specialist CRO. In coming together with
Cu-Tech, Synteract has created a dedicated center of dermatology
development, making the combined company the leading midsized global CRO
for dermatology clinical trials.

Cu-Tech
is an industry-renowned dermatology CRO with more than two decades
of experience, having managed 130+ dermatology trials. The New
Jersey-based CRO is known for its strong relationships with its clients
and investigative sites, as well as for its expertise in working across
a variety of dermatological indications.

Steve
Powell, CEO of Synteract, says, “The acquisition of Cu-Tech
represents the next step in our strategy to specialize in targeted areas
of clinical development. We have combined Synteract’s existing base of
experience in dermatology with the focused strength and expertise that
Cu-Tech has provided its customers for over 20 years. Dermatology is
poised for continued strong growth, and in acquiring Cu-Tech, we have
created a leading CRO for dermatological services and site connections.
In recognition of their leadership in the dermatology sector, we will
support the Cu-Tech team in their current form. Dermatology is now our
fifth specialized area of focus, alongside oncology, neuro-degenerative
diseases, rare and orphan diseases, and pediatrics.”

With over 120 dermatologic trials conducted including more than 17,000
patients, Synteract draws on a longstanding dedication to dermatological
drug development in complex Phase I-IV clinical trials. By adding a
center of development in dermatology, Synteract has positioned itself to
better meet sponsors’ specific needs, including addressing stringent
trial demands, delivering consistency of study conduct across
investigational sites and ensuring accuracy in reporting. Synteract
brings international delivery capabilities to the relationship with
Cu-Tech as well as specific services in feasibility, biostatistics,
clinical operations, data management, medical writing and regulatory
expertise.

Kathleen (Kit) Ashenfelter, executive director of operations and
development at Cu-Tech, who will now also serve as the head of the
Synteract dermatology center of development, says, “Cu-Tech has always
offered best-in-class results. We are committed to maintaining the high
quality of service that clients and investigative sites have come to
expect. Working with Synteract allows us to bring enhanced capabilities
to our clients, including an international presence.”

Jack
Shannon, Synteract’s chief commercial officer, adds, “Dermatology is
a growing area of clinical development worldwide. The combination of
Cu-Tech and Synteract creates the leading dermatology CRO with global
capabilities and unparalleled access to sites and patients. Our focus on
the development of novel and in-demand dermatology drugs provides our
customers with dedicated research services that are unmatched in the
market.”

About Synteract

With 800 staff members across 21 countries, Synteract
is an innovative, full-service contract research organization supporting
biopharmaceutical companies in all phases of clinical development to
help bring new medicines to market. Synteract has conducted nearly 4,000
studies on six continents and in more than 60 countries, working with
more than 26,000 investigative sites and nearly 750,000 patients. It has
contributed to more than 240 product approvals. The CRO offers a notable
depth of expertise in its centers of development in oncology and
neuro-degenerative indications, as well as rare and orphan, pediatric,
and immunotherapy studies, and now dermatology. Connect on LinkedIn
and Twitter.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180711005210/en/

Leave a Comment